Last edition
News about "Pfizer"
Pfizer and Cipla Form Exclusive Marketing Partnership for Select Brands in India
Pfizer and Cipla have joined forces in an exclusive marketing and distribution agreement for select brands in India. The collaboration aims to improve access and availability of these key medicines, ensuring patients across the country benefit from a wider reach and streamlined supply.
Pfizer | 19/12/2025 | By News Bureau
Adaptive Biotechnologies Signs Two Immune Receptor Licensing Deals with Pfizer
Adaptive Biotechnologies has signed two immune receptor licensing agreements with Pfizer, covering a T-Cell Receptor (TCR) discovery collaboration in rheumatoid arthritis and access to Adaptive’s proprietary TCR-antigen datasets for immunology R&D.
Pfizer | 16/12/2025 | By News Bureau
Yao Pharma and Pfizer Sign Exclusive Collaboration Deal
Yao Pharma has entered into an exclusive global licensing agreement with Pfizer, granting rights to develop, manufacture, and commercialise its oral small-molecule GLP-1 receptor agonists, including lead candidate YP05002. The partnership aims to advance next-generation metabolic therapies with worldwide reach.
Pfizer | 10/12/2025 | By Akanki
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Pfizer | 24/11/2025 | By Dineshwori
Pfizer Completes Acquisition of Metsera
Pfizer has finalised its acquisition of Metsera, adding a portfolio of differentiated, clinical-stage obesity therapies with the potential to redefine future treatment standards. The deal strengthens and reshapes Pfizer’s internal medicine portfolio, positioning the company to compete more aggressively in therapeutic areas, globally.
Pfizer | 14/11/2025 | By Dineshwori
Pfizer Cuts Majority of Its BioNTech Stake in Strategic Realignment
After the sale, Pfizer now holds around 1.66 million American Depositary Shares, valued at roughly USD 163 million as of late September 2025.
Pfizer | 14/11/2025 | By Darshana
Novo Nordisk Submits Updated Proposal to Acquire Metsera in Multi-Billion-Dollar Deal
Novo Nordisk has confirmed that it has submitted an updated, unsolicited proposal to acquire Metsera, which has been declared superior by Metsera’s board of directors.
Pfizer | 06/11/2025 | By Dineshwori | 109
Pfizer has announced positive topline results from its Phase 3 HER2CLIMB-05 trial evaluating TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a first-line maintenance therapy for patients with HER2-positive (HER2+) metastatic breast cancer (MBC).
Pfizer | 15/10/2025 | By Dineshwori | 121
Pfizer signs Agreement with US Government to Lower Drug Costs for American Patients
Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in other developed countries and pricing newly launched medicines at parity with other key developed markets.
Pfizer | 01/10/2025 | By Dineshwori | 103
Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline
Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.
Pfizer | 23/09/2025 | By Dineshwori | 101
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy